Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Change in Accured Expenses (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Change in Accured Expenses data on record, last reported at $1.2 million in Q4 2021.

  • For Q4 2021, Change in Accured Expenses rose 253.84% year-over-year to $1.2 million; the TTM value through Dec 2021 reached $3.4 million, up 245.88%, while the annual FY2025 figure was $33000.0, 99.79% down from the prior year.
  • Change in Accured Expenses reached $1.2 million in Q4 2021 per COGT's latest filing, up from $602000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.7 million in Q2 2021 and bottomed at -$2.0 million in Q1 2021.
  • Average Change in Accured Expenses over 4 years is $357625.0, with a median of $250500.0 recorded in 2019.
  • Peak YoY movement for Change in Accured Expenses: crashed 259.42% in 2020, then soared 844.96% in 2021.
  • A 4-year view of Change in Accured Expenses shows it stood at -$124000.0 in 2018, then soared by 578.23% to $593000.0 in 2019, then plummeted by 227.49% to -$756000.0 in 2020, then skyrocketed by 253.84% to $1.2 million in 2021.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $1.2 million in Q4 2021, $602000.0 in Q3 2021, and $3.7 million in Q2 2021.